An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough

This was an open-label feasibility study that examined escalating doses of memantine (10–40 mg/day) in patients with refractory chronic cough enrolled at a tertiary cough clinic in the United Kingdom. The primary endpoint was the change from baseline in awake cough frequency after 4 weeks' treatment with the maximum tolerated dose of memantine; secondary endpoints were the change from baseline in CQLQ scores and tolerability. Cough frequency was measured at baseline and at the end of treatment using the Vitalograph VitaloJAK 24-hour ambulatory cough monitoring device.